Japan breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 9.6% during the forecast period. The major factors that drive the market include the high prevalence of breast cancer, awareness programs by government and private organizations. According to the National cancer centre, breast cancer is the most common cancer in women, about 89,100 cases are estimated in 2017. Breast cancer is the 5th largest cause of mortality in Japan, it was estimated at about 14,400 in 2017. The increasing incidences enable the growth of the screening rates thus also grow the market in this region. The ‘Pink Ribbon Festival’ initiated by the Japan Cancer Society that enables to raise public awareness of the importance of early detection, diagnosis and treatment of breast cancer.